Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Oleoylethanolamide (OEA) is a naturally occurring lipid mediator produced in the small intestine. It has attracted scientific interest due to its role in the regulation of feeding, body weight, and lipid metabolism. Several preclinical studies in rodents have shown that OEA can reduce food intake, stimulate fat utilization, and modulate energy homeostasis by activating peroxisome proliferator-activated receptor-alpha (PPAR-α). These effects have suggested a potential role for OEA in the management of metabolic syndrome, a cluster of conditions that includes obesity, insulin resistance, dyslipidemia, and hypertension.

Human evidence remains limited but promising. Small-scale clinical trials and pilot studies indicate that OEA supplementation may reduce appetite and improve some markers of metabolic health, such as waist circumference and lipid profiles, in overweight or obese individuals. For example, a 2018 double-blind, placebo-controlled trial found that OEA supplementation led to significant reductions in body weight, waist circumference, and LDL cholesterol over 8 weeks in overweight subjects. However, larger and longer-duration studies are needed to confirm these benefits and to clarify the impact on the broader spectrum of metabolic syndrome features.

In summary, scientific evidence—primarily from animal studies and early-phase human trials—supports the potential use of OEA for metabolic syndrome. The current level of evidence is moderate (rated 3/5), and more robust clinical trials are required before OEA can be considered a standard therapy for this condition.

More about Oleoylethanolamide
More about Metabolic Syndrome

Other ingredients used for Metabolic Syndrome

Other health conditions supported by Oleoylethanolamide

Products containing Oleoylethanolamide